Showing 6001-6010 of 8687 results for "".
- Onset Dermatologics Acquires Worldwide Rights to Clindagel from Galderma Laboratorieshttps://practicaldermatology.com/news/20131031-onset_dermatologics_acquires_worldwide_rights_to_clindagel_from_galderma_laboratories/2459425/Onset Dermatologics, LLC recently announced the acquisition of Clindagel (clindamycin phosphate gel 1%), a prescription topical antibiotic for the treatment of acne, from Galderma Laboratories. Clindagel is the only FDA-approved topical form
- Subliminally Exposed to be Presented at Cosmetic Surgery Forumhttps://practicaldermatology.com/news/20131029-subliminally_exposed_to_be_presented_at_cosmetic_surgery_forum/2459426/Based on the New York Times and USA Today best seller, Subliminally Exposed, Dr. Steven Dayan and Valerie Monroe will present at this year's Cosmetic Surgery Fo
- Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2a Cellulite Study of Collegenase Clostridium Histolyticumhttps://practicaldermatology.com/news/20131024-auxilium_pharmaceuticals_inc_announces_first_patient_dosed_in_phase_2a_cellulite_study_of_collegenase_clostridium_histolyticum/2459430/Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully-integrated specialty biopharmaceutical company, today announced the first patient dosed in its Phase 2a study of collagenase clostridium histolyticum (or "CCH") for the treatment of edematous fibrosclerotic panniculopathy ("EFP"), commonly known
- Pfizer Announces Top-Line Results of Two Phase III Clinical Trials Of Tofacitinibhttps://practicaldermatology.com/news/20131021-pfizer_announces_top-line_results_of_two_phase_iii_clinical_trials_of_tofacitinib/2459433/Pfizer, Inc. recently announced top-line results from two Phase III clinical trials of tofacitinib, a novel, oral Janus kinase (JAK) inhibitor that is being investigated for the treatment of adults with moderate-to-severe chro
- FDA Files sBLA for Xolair in Patients with Chronic Idiopathic Urticariahttps://practicaldermatology.com/news/20131011-genentech_files_sbla_for_xoliar_in_patients_with_cronic_idiopathic_urticaria/2459437/The FDA accepted and filed Genentech's supplemental Biologics License Application (sBLA) for subcutaneous use of Xolair® (omalizumab) in people with Chronic Idiopathic Urticaria (CIU) who remained symptomatic despite treatment with H1-antihistamine therapy at approved doses. The filing was primarily
- Hair Restoration Doctors Name Best Celebrity Hair, Meeting Convenes October 23https://practicaldermatology.com/news/20131010-hair_restoration_doctors_name_best_celebrity_hair_meeting_convenes_october_23/2459438/Singer/songwriter John Mayer and “Modern Family” star Sofia Vergara are the male and female celebrities with the most sought-after hair, according to results of the International Society of Hair Restoration Surgery (ISHRS) member survey released rec
- Ellzey Coding Solutions Introduces ICD-10 for Dermatology Manualhttps://practicaldermatology.com/news/20131010-ellzey_coding_solutions_introduces_icd-10_for_dermatology_manual/2459440/Ellzey Coding Solutions, Inc., recently released an ICD-10 coding manual specifically for dermatologists. The 2014 ICD-10 for Dermatology program is a tool that can be used to prepare dermatologists and staff with what they need to know about the ICD-10-CM diagnosis coding syste
- KYTHERA Biopharmaceuticals Announces Proposed Public Offering of Common Stockhttps://practicaldermatology.com/news/20131007-kythera_biopharmaceuticals_announces_proposed_public_offering_of_common_stock/2459441/KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced it has commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of $100 million. All of the shares of the common stock to be sold in the offering will be offered by KYTHERA. KYTHERA intend
- Strathspey Crown's Alphaeon Acquires Toxin Developer Evolus, Inc.https://practicaldermatology.com/news/20131004-strathspey_crowns_alphaeon_acquires_toxin_developer_evolus_inc/2459443/Strathspey Crown Holdings, LLC has acquired Evolus, Inc. of Santa Barbara, California for an undisclosed amount. As part of the transaction, Strathspey Crown's wholly-owned subsidiary, Alph
- MELA Sciences Appoints Dr. Darrell Rigel as Chief Medical Advisor to Its Board of Directorshttps://practicaldermatology.com/news/20131001-mela_sciences_appoints_dr_darrell_rigel_as_chief_medical_advisor_to_its_board_of_directors/2459445/MELA Sciences, Inc., announced that Darrell S. Rigel, MD, MS, Clinical Professor of Dermatology at New York University, Langone Medical Center, has been appointed Chief Medical Advisor to the Company's Board of Directors. Dr. Rigel is a Clinical Profes